CRNX vs. AUPH

Last updated Apr 2, 2026

Compare and contrast key facts about Crinetics Pharmaceuticals, Inc. (CRNX) and Aurinia Pharmaceuticals Inc. (AUPH).

Performance

CRNX vs. AUPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Crinetics Pharmaceuticals, Inc. (CRNX) and Aurinia Pharmaceuticals Inc. (AUPH). The values are adjusted to include any dividend payments, if applicable.

CRNX vs. AUPH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
CRNX Crinetics Pharmaceuticals, Inc.	-21.44%	-8.96%	43.70%	94.43%	-35.59%	101.35%	-43.76%	-16.34%	22.36%
AUPH Aurinia Pharmaceuticals Inc.	-3.01%	77.62%	-0.11%	108.10%	-81.11%	65.37%	-31.74%	197.07%	19.65%

Fundamentals

Market Cap CRNX : $3.44B AUPH : $2.15B
EPS CRNX : -$4.95 AUPH : $2.06
PS Ratio CRNX : 634.38 AUPH : 7.61
PB Ratio CRNX : 3.47 AUPH : 3.69
Total Revenue (TTM) CRNX : $5.42M AUPH : $283.06M
Gross Profit (TTM) CRNX : $5.88M AUPH : $250.39M
EBITDA (TTM) CRNX : -$513.87M AUPH : $109.83M

Returns By Period

In the year-to-date period, CRNX achieves a -21.44% return, which is significantly lower than AUPH's -3.01% return.

CRNX

• 1D: 0.69%
• 1M: -10.10%
• YTD: -21.44%
• 6M: -12.11%
• 1Y: 19.43%
• 3Y*: 31.56%
• 5Y*: 17.98%
• 10Y*: —

AUPH

• 1D: 4.39%
• 1M: 8.87%
• YTD: -3.01%
• 6M: 35.70%
• 1Y: 92.17%
• 3Y*: 12.17%
• 5Y*: 3.32%
• 10Y*: 18.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRNX vs. AUPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRNX

CRNX Risk / Return Rank: 50
CRNX Sharpe Ratio Rank: 53
CRNX Sortino Ratio Rank: 54
CRNX Omega Ratio Rank: 51
CRNX Calmar Ratio Rank: 46
CRNX Martin Ratio Rank: 47

AUPH

AUPH Risk / Return Rank: 91
AUPH Sharpe Ratio Rank: 90
AUPH Sortino Ratio Rank: 88
AUPH Omega Ratio Rank: 88
AUPH Calmar Ratio Rank: 95
AUPH Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRNX vs. AUPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Crinetics Pharmaceuticals, Inc. (CRNX) and Aurinia Pharmaceuticals Inc. (AUPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRNX	AUPH	Difference
Sharpe ratio Return per unit of total volatility	0.33	2.04	-1.71
Sortino ratio Return per unit of downside risk	1.00	2.66	-1.67
Omega ratio Gain probability vs. loss probability	1.11	1.38	-0.26
Calmar ratio Return relative to maximum drawdown	0.22	5.81	-5.59
Martin ratio Return relative to average drawdown	0.64	12.66	-12.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRNX vs. AUPH - Sharpe Ratio Comparison

The current CRNX Sharpe Ratio is 0.33, which is lower than the AUPH Sharpe Ratio of 2.04. The chart below compares the historical Sharpe Ratios of CRNX and AUPH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRNX	AUPH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.33	2.04	-1.71
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.28	0.05	+0.23
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.24	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	0.17	-0.09

Correlation

The correlation between CRNX and AUPH is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CRNX vs. AUPH - Dividend Comparison

Neither CRNX nor AUPH has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CRNX vs. AUPH - Drawdown Comparison

The maximum CRNX drawdown since its inception was -68.70%, smaller than the maximum AUPH drawdown of -87.58%. Use the drawdown chart below to compare losses from any high point for CRNX and AUPH.

Drawdown Indicators

	CRNX	AUPH	Difference
Max Drawdown Largest peak-to-trough decline	-68.70%	-87.58%	+18.88%
Max Drawdown (1Y) Largest decline over 1 year	-40.33%	-15.91%	-24.42%
Max Drawdown (5Y) Largest decline over 5 years	-57.88%	-87.58%	+29.70%
Max Drawdown (10Y) Largest decline over 10 years	—	-87.58%	—
Current Drawdown Current decline from peak	-39.74%	-53.23%	+13.49%
Average Drawdown Average peak-to-trough decline	-37.32%	-49.17%	+11.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.05%	7.30%	+6.75%

Volatility

CRNX vs. AUPH - Volatility Comparison

Crinetics Pharmaceuticals, Inc. (CRNX) and Aurinia Pharmaceuticals Inc. (AUPH) have volatilities of 13.73% and 13.51%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRNX	AUPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.73%	13.51%	+0.22%
Volatility (6M) Calculated over the trailing 6-month period	34.83%	26.87%	+7.96%
Volatility (1Y) Calculated over the trailing 1-year period	59.15%	45.40%	+13.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	63.99%	68.71%	-4.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	65.36%	74.42%	-9.06%

Financials